News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News AHA 2024 OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain Todd Neale November 18, 2024
News Conference News AHA 2024 One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024 Shelley Wood November 14, 2024
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Conference News AHA 2020 Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib Todd Neale November 14, 2020
News Conference News AHA 2019 Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR Todd Neale November 17, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News AHA 2018 Complications Following TAVR Are Going Down, US Data Show Yael L. Maxwell November 20, 2018
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016